Compare Adaptive Biotechnologies Corp (ADPT) vs NICE Ltd (NICE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs NICE Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while NICE Ltd trades at $96.93 (market cap $5.88B). The key difference: NICE Ltd is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | NICE | |
|---|---|---|
Market Cap | $3.33B | $5.88B |
Sector | Health | Technology |
52-Week High | $22.37 | $171.98 |
52-Week Low | $10.24 | $83.15 |
Enterprise Value | $3.19B | $5.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NICE trades at $97.17, up 0.44% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company shows strong profitability with a 65.79% gross margin and 17.57% net income margin, while recent news highlights AI platform expansions with Sopra Steria and AWS European Sovereign Cloud deployment (Business Wire, 2026-07-01).
The stock presents a compelling value opportunity with a P/E of 11.53 below sector averages, supported by a $124.88 analyst price target implying 28% upside. Risks include projected net income decline to $530M in 2026 and overbought short-term RSI levels. Wall Street sentiment remains positive with 13 buy ratings and no sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
